Development of novel EGFR tyrosine kinase inhibitors for the management of glioma, head and neck and other cancers

Funded Activity Summary

Abnormalities in EGF-EGFR family signalling pathways have been implicated in many human cancers including glioma, squamous cell carcinome of the head and neck, colon, ovary and prostate, and are associated with poor clinical prognosis, non-responsiveness to chemotherapy, and decreased survival. Inhibitors of these pathways would therefore be useful anti-cancer pharmaceuticals. This proposal outlines experiments aimed at understanding the role of the individual EGFR family members in controlling a complex signalling network, and the development of novel small molecule inhibitors of these pathways which are specific for individual EGFR family members and which should prove effective in the management of many forms of cancer. Additionally, the potential synergy of these inhibitors in combination therapy with other anti-cancer drugs and reagents which induce cell death will be investigated. These small molecule pharmaceuticals could easily be produced commercially, and taken into clinical trials, in Australia.

Funded Activity Details

Start Date: 01-01-2001

End Date: 01-01-2003

Funding Scheme: NHMRC Project Grants

Funding Amount: $196,527.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

EGF/EGFR signalling | cancer | cancer therapy | colonic carcinoma | cytosensor analysis | glioblastoma | small molecule inhibitors | squamous cell carcinoma of head and neck

Related Links